Figure 3.

DTT treatment of PGRN abolishes its binding to TNFR, whereas enhances its binding to Sortilin. (A) DTT treatment disrupts the direct binding between PGRN and TNFR2. PGRN from Liu’s lab was pretreated with or without 10 mmol/L DTT, and various amounts of PGRN, as indicated, were coated on the plate. Binding to TNFR2 was measured by solid phase assay. (B) DTT treatment enhances the binding of PGRN to Sortilin. Similar to (A), same dosages of PGRN from Liu’s lab were pretreated with or without 10 mmol/L DTT, the binding to Sortilin was measured. Adapted from Jian J, et al, FEBS letters, 2013